Pacific Biosciences is a leading provider of sequencing technologies, with a focus on long-range sequencing and real-time data analysis.
Their products include the Sequel System, which offers high-throughput sequencing capabilities, and the Sequel II System, which provides even faster and more accurate results.
The company's services include data analysis and interpretation, as well as custom sequencing solutions for research and clinical applications.
Pacific Biosciences is a key player in the genomics market, with a strong presence in the fields of human genetics, infectious disease, and synthetic biology.
A fresh viewpoint: Tech Data
Sequencing Technology and Instruments
Pacific Biosciences has been at the forefront of sequencing technology since its inception. The company's first scientific instrument, the PacBio RS, was released to a limited set of customers in late 2010, with full commercial release in early 2011.
Sequencing provider GATC Biotech was selected by Pacific Biosciences as its first European service provider in late 2010. This marked a significant milestone for the company's expansion into the European market.
Broaden your view: European Reliance
The PacBio RS II, a new version of the sequencer, was released in April 2013. It produced longer sequence reads and higher throughput than the original RS instrument, making it a significant upgrade.
The RS instrument will officially be supported until the end of 2021. This means that customers who have invested in the technology can continue to rely on it for at least a few more years.
In September 2015, the company released a new sequencing instrument, the Sequel System. It offered increased sequencing capacity at a smaller size and lower price compared to the PacBio RS II.
PacBio launched a new sequencing system in October 2022. This system can sequence 1,300 human genomes per year, a significant increase from the 86 per year of the previous PacBio sequencing machines.
Recommended read: Per Aarsleff
Products and Services
Pacific Biosciences has a range of products and services that cater to the needs of researchers and scientists. Their secondary analysis software, SMRT Analysis, was open source.
One of their notable products is SMRT Link, a secondary analysis application for the Sequel system. This application is a significant upgrade from their previous secondary analysis software.
In 2013, Pacific Biosciences released two new bioinformatics tools: HGAP for automated genome assembly and Quiver for finishing. These tools have been instrumental in advancing genomic research.
Reagents and Cells
To use these instruments, customers must also purchase reagent packs for DNA preparation and sequencing.
These reagent packs are essential for the DNA preparation and sequencing process, making them a crucial part of the overall system.
The SMRT Cells are small consumables that contain tens of thousands of zero-mode waveguides, allowing for DNA sequencing to take place.
Newer systems have a higher density of cells, with 25 million zero-mode waveguides, enabling faster DNA sequencing.
The size of the SMRT Cells is slightly less than one-centimeter square, making them compact and easy to handle.
Software And Applications
Their secondary analysis bioinformatics product for the RS system was open source and called “SMRT Analysis”. This product was a game-changer for researchers who needed to analyze their data.
If this caught your attention, see: Tiktok Shop Product Research
The company reorganized the secondary analysis software for the Sequel system as the "SMRT Link" application. This made it easier for users to access and utilize the software.
In 2013, the company released new bioinformatics tools for automated genome assembly, called HGAP. This tool was a significant improvement over previous methods.
HGAP was designed to make genome assembly faster and more efficient.
Stock Performance
Pacific Biosciences' stock performance has been a mixed bag.
The company's current share price is $1.49, which is a 18.25% increase from last month. Over the past year, the stock has decreased by 13.37%, and over the past five years, it's dropped by a whopping 88.96%.
The 52-week high for Pacific Biosciences' stock was $2.72, while the 52-week low was $0.85. This indicates a significant fluctuation in the company's stock price over the past year.
Here's a comparison of Pacific Biosciences' stock performance with the US Life Sciences industry and the US market:
As you can see, Pacific Biosciences' stock has underperformed the US market, which returned 18.7% over the past year. However, it has matched the US Life Sciences industry, which returned -14.1% over the same period.
The company's stock price has been relatively stable over the past three months, with an average weekly movement of 10.2%. This is slightly higher than the Life Sciences industry average of 8.6%, but lower than the market average of 6.4%.
For your interest: 454 Life Sciences
Market Comparison
Pacific Biosciences' long-read sequencing technology offers a significant advantage over traditional short-read sequencing methods, with the ability to produce reads of up to 100,000 base pairs.
This is particularly beneficial for de novo genome assembly and structural variant detection, where the longer reads can provide more accurate and complete information.
The company's technology is also more accurate than some of its competitors, with a reported error rate of 0.5% or less for certain applications.
Illumina: Attempted Acquisition
Illumina attempted to acquire PacBio in 2018 for $1.2 billion in cash, but the deal was abandoned in 2020 due to regulatory issues.
The Federal Trade Commission sued to block the acquisition in December 2019, which led to the deal being abandoned.
Illumina agreed to pay a $98 million termination fee to PacBio, as well as $22 million and $6 million in deal extension payments in February and March 2020, respectively.
Here are some key points about the attempted acquisition:
- PacBio was listed on the Nasdaq.
- Illumina is a technology company based in the San Francisco Bay Area.
- PacBio is a biotechnology company established in 2004.
Pacb Competitors
Pacb's competitors are chosen from the Health Technology sector and Medical Specialties group. This sector classification helps us understand the competitive landscape of Pacb.
Pacb has a market capitalization of $447.55 million, placing it in the small capitalization category. This means Pacb is a relatively small company in terms of market value.
To give you a better idea of Pacb's competitors, here's a list of some of the companies in the same sector and market capitalization range:
- Companies in the Health Technology sector and Medical Specialties group
Note that the article doesn't provide specific competitor names, but it gives us an idea of the sector and market size that Pacb operates in.
Frequently Asked Questions
Is Pacific Biosciences a good stock to buy?
Pacific Biosciences has a Moderate Buy rating with 3 buy ratings and 0 sell ratings, suggesting it's a potentially attractive investment. However, with an average price target of $2.08, it's essential to weigh the pros and cons before making a decision.
What is the difference between Illumina and PacBio?
Illumina and PacBio are two types of DNA sequencing technologies with distinct error profiles: Illumina has low error rates but may struggle with specific sequences, while PacBio's errors are random and can be improved with increased coverage
Featured Images: pexels.com
